ZNF212 Knockout cell line (ACHN)

CRISPR knockout cell lines are engineered through targeted genome editing to eliminate gene function, supporting studies of cellular biology, disease mechanisms, and drug discovery.

ZNF212 (zinc finger protein 212) encodes a member of the C2H2-type zinc finger protein family. Its zinc finger domains are characteristic of proteins involved in interactions with nucleic acids or other proteins and may support regulation of gene expression and cellular development. The specific molecular targets and biological functions of ZNF212 have not been fully characterized.

Initiated in November 1979, ACHN is a well-established human cell line derived from the malignant pleural effusion of a 22-year-old Caucasian male with widely metastatic renal adenocarcinoma. The cells were originally seeded directly into culture flasks in Eagle’s MEM supplemented with 10% FBS, and maintained through passages for 150 days before being inoculated subcutaneously into nude mice, where they formed palpable, locally invasive tumors within four weeks. Notably, both the parental ACHN cells and those recovered from the nude mouse tumors are distinctly growth-inhibited by human interferons, making ACHN a premier in vitro and in vivo model platform for investigating renal oncology progression, cytokine responses, and preclinical drug evaluation.

Before delivery, each clone is authenticated by STR, tested for sterility and mycoplasma, and genotype‑verified by two‑round PCR‑sequencing. Comprehensive QC data accompany every shipment to support reproducible research.